47. Name this bone marking/structure.
Category: Uncategorized
Which of the following can be used for quick relief/rescue t…
Which of the following can be used for quick relief/rescue treatment in pediatric asthma? (Select all that apply)
16. Name this bone marking/structure.
16. Name this bone marking/structure.
Allopurinol is a mainstay of uric acid lowering therapy. Whi…
Allopurinol is a mainstay of uric acid lowering therapy. Which of the following describes Allopurinol’s mechanism of action?
A 72-year-old female with newly diagnosed stage 1 hypertensi…
A 72-year-old female with newly diagnosed stage 1 hypertension and no compelling comorbidities is started on hydrochlorothiazide. Which laboratory abnormality is most likely?
BB is 2 yo male with intermittent asthma. He is prescribed…
BB is 2 yo male with intermittent asthma. He is prescribed an inhaled corticosteroid and a short-acting beta 2-agonist (SABA). Which of the prescribed medications is used to reduce inflammation and improve symptoms and lung function?
A 64-year-old female with established atherosclerotic cardio…
A 64-year-old female with established atherosclerotic cardiovascular disease (ASCVD) is taking maximally tolerated atorvastatin 80 mg daily. Her LDL-C remains 92 mg/dL. What is the most appropriate next step in management?
7. Name this cell.
7. Name this cell.
Diltiazem and Verapamil are indicated in tachycardias inclu…
Diltiazem and Verapamil are indicated in tachycardias including atrial fibrillation. A primary side effect of verapamil is:
A 71-year-old female with severe COPD (FEV₁ 38% predicted) p…
A 71-year-old female with severe COPD (FEV₁ 38% predicted) presents for follow-up. She has chronic bronchitis symptoms and reports two hospitalizations for COPD exacerbations in the past year despite adherence to triple inhaler therapy (fluticasone/umeclidinium/vilanterol). She quit smoking 3 years ago. FEV 1= 42%. Blood eosinophil count is 90 cells/µL. She denies asthma history. Oxygen saturation is 93% on room air. BMI is 21 kg/m². Which of the following is the most appropriate next step in pharmacologic management?